Thromb Haemost 1987; 57(01): 049-054
DOI: 10.1055/s-0038-1651060
Original Articles
Schattauer GmbH Stuttgart

Evaluation of Monoclonal Antifibrin Antibodies by Their Binding to Human Blood Clots

Chiau S Liau
The Cellular and Molecular Research Laboratory, Cardiac Unit, Massachusetts General Hospital, and Departments of Pathology and Medicine, Harvard Medical School, Boston, MA, USA
,
Edgar Haber
The Cellular and Molecular Research Laboratory, Cardiac Unit, Massachusetts General Hospital, and Departments of Pathology and Medicine, Harvard Medical School, Boston, MA, USA
,
Gary R Matsueda
The Cellular and Molecular Research Laboratory, Cardiac Unit, Massachusetts General Hospital, and Departments of Pathology and Medicine, Harvard Medical School, Boston, MA, USA
› Author Affiliations
Further Information

Publication History

Received 20 December 1985

Accepted after revision 28 October 1986

Publication Date:
06 July 2018 (online)

Preview

Summary

The primary goal of this study was to develop a method for evaluating fibrin-specific antibodies as thrombus detecting agents. The apparatus and assay conditions were chosen by testing antibody 64C5, which binds to the amino terminus of the fibrin beta chain, for its ability to bind to human blood clots. Using 125I-labeled antibody 64C5, the effects of antibody concentration, clot shape, clot mass, temperature, and flow rate were tested. Increased antibody binding was observed when antibody concentration, clot mass and temperature were increased. Under one set of conditions, six 125I-labeled monoclonal antifibrin antibodies (four specific for the beta chain, two specific for the alpha chain) were tested for their binding to retracted clots of human blood. Two radioiodinated antidigoxin antibodies were used as a control. Beta chain-specific antibody 59D8, which provided the highest level of binding to clot, bound 14-fold better than the control antidigoxin antibody. Neither alpha chain-specific antibody bound to clotted blood. To examine the in vivo relevance of the in vitro binding to clots, the uptake of antibody 64C5 was assessed for its binding to human fibrin clotted within the jugular vein of a rabbit. The correlation coefficient between in vitro and in vivo uptake as a function of clot weight was calculated to be 0.91. Thus, in vitro binding of monoclonal antifibrin antibodies to human blood clots was judged to be a realistic method for the comparison and selection of an ideal antifibrin antibody for detailed in vivo testing.